Results 151 to 160 of about 52,475 (270)
Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report [PDF]
, 2014 Naveen Nannapaneni +3 more
openalex +1 more source
Periprocedural Off-label Use of Rivaroxaban in Patient with Atrial Fibrillation and a Persistent Left Atrial Appendage Thrombus Despite Standard Anticoagulation Therapy: A Case Report [PDF]
, 2023 Archil Chukhrukidze, Zviad Kereselidze
openalex +1 more source
Rare but relevant: Cannabis use and myocardial infarction
Addiction, Volume 120, Issue 12, Page 2580-2584, December 2025.Abstract Pre‐clinical research and case reports have linked cannabis use to myocardial infarction (MI) since the 1970s. The association with MI may be specific to certain types and patterns of cannabis use as well as certain consumer characteristics; however, due to limited data availability, meta‐analyses examining the association between cannabis use
Prianka Padmanathan, Emmert Roberts
wiley +1 more source
Rivaroxaban administration after acute ischemic stroke: The RELAXED study
, 2019 Masahiro Yasaka +9 more
openalex +2 more sources
Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom [PDF]
, 2021 Luis A. Garcı́a Rodrı́guez +4 more
openalex +1 more source
Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?
, 2022 Kunal Deokar +4 more
openalex +1 more source
Fundamental &Clinical Pharmacology, Volume 39, Issue 6, December 2025.ABSTRACT Background Direct‐acting oral anticoagulants (DOACs) have largely replaced warfarin for stroke prevention in patients with atrial fibrillation, yet their population‐level impact on health outcomes and costs remains unclear. We examined whether the widespread uptake of DOACs was associated with changes in hospitalization rates and costs for ...
Tony Antoniou +4 more
wiley +1 more source
Obesity Reviews, Volume 26, Issue 12, December 2025.ABSTRACT Introduction Although the physiologic alterations seen in obesity often affect the pharmacokinetics and pharmacodynamics of drugs, most clinical trials do not consider these aspects specifically for this population. To date, there is no list of potentially inappropriate medications for patients living with obesity. The aim of this study was to
Sarah Berdot +17 more
wiley +1 more source
Pacing and Clinical Electrophysiology, Volume 48, Issue 12, Page 1444-1450, December 2025.ABSTRACT Background The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was ...
Daniel S. Cheah +4 more
wiley +1 more source